- Home
- WLKP vs STOK Comparison
WLKP vs STOK Comparison
Compare WLKP & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLKP
- STOK
- Stock Information
- Founded
- WLKP 2014
- STOK 2014
- Country
- WLKP United States
- STOK United States
- Employees
- WLKP N/A
- STOK N/A
- Industry
- WLKP Major Chemicals
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- WLKP Industrials
- STOK Health Care
- Exchange
- WLKP Nasdaq
- STOK Nasdaq
- Market Cap
- WLKP 819.6M
- STOK 721.4M
- IPO Year
- WLKP 2014
- STOK 2019
- Fundamental
- Price
- WLKP $23.00
- STOK $11.68
- Analyst Decision
- WLKP
- STOK Strong Buy
- Analyst Count
- WLKP 0
- STOK 8
- Target Price
- WLKP N/A
- STOK $21.83
- AVG Volume (30 Days)
- WLKP 41.8K
- STOK 667.4K
- Earning Date
- WLKP 02-18-2025
- STOK 11-05-2024
- Dividend Yield
- WLKP 8.21%
- STOK N/A
- EPS Growth
- WLKP 8.66
- STOK N/A
- EPS
- WLKP 1.75
- STOK N/A
- Revenue
- WLKP $1,143,109,000.00
- STOK $16,742,999.00
- Revenue This Year
- WLKP N/A
- STOK $103.66
- Revenue Next Year
- WLKP $5.56
- STOK N/A
- P/E Ratio
- WLKP $13.11
- STOK N/A
- Revenue Growth
- WLKP N/A
- STOK 81.08
- 52 Week Low
- WLKP $21.19
- STOK $4.09
- 52 Week High
- WLKP $24.34
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- WLKP 37.98
- STOK 44.25
- Support Level
- WLKP $23.68
- STOK $10.61
- Resistance Level
- WLKP $24.20
- STOK $12.58
- Average True Range (ATR)
- WLKP 0.46
- STOK 0.95
- MACD
- WLKP -0.15
- STOK -0.12
- Stochastic Oscillator
- WLKP 0.00
- STOK 28.34
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develop ethyelene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.